Erasca, Inc. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2025-05-13: Form 10-Q; Exhibit 10.1; Description Non-Employee Director Compensation Program.
- 2024-08-12: Form 10-Q; Exhibit 10.2; Description License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc..
- 2024-08-12: Form 10-Q; Exhibit 10.1; Description License Agreement, dated May 15, 2024, by and between Guangzhou Joyo Pharmatech Co., Ltd., and Erasca, Inc..
- 2024-03-28: Form 8-K; Exhibit 10.1; Description Stock Purchase Agreement, dated March 27, 2024, by and between Erasca, Inc. and each of the purchasers party thereto.
| Filed | Form | Exhibit | Description |
|---|
| 2025-05-13 | 10-Q | 10.1 | Non-Employee Director Compensation Program |
|---|
| 2024-08-12 | 10-Q | 10.2 | License Agreement, dated May 14, 2024, by and between Medshine Discovery Inc., and Erasca, Inc. |
|---|
| 2024-08-12 | 10-Q | 10.1 | License Agreement, dated May 15, 2024, by and between Guangzhou Joyo Pharmatech Co., Ltd., and Erasca, Inc. |
|---|
| 2024-03-28 | 8-K | 10.1 | Stock Purchase Agreement, dated March 27, 2024, by and between Erasca, Inc. and each of the purchasers party thereto |
|---|
| 2024-03-27 | 10-K | 10.18 | Erasca, Inc. Non-Employee Director Compensation Program |
|---|
| 2023-11-09 | 10-Q | 10.1 | First Amendment to Exclusive License Agreement, dated August 7, 2023, by and between Novartis Pharma AG and the Registrant |
|---|
| 2023-08-10 | 10-Q | 10.1 | Amended and Restated Employment Letter Agreement, dated April 10, 2023, between Shannon R. Morris, M.D., Ph.D. and Erasca, Inc. |
|---|
| 2023-03-23 | 10-K | 10.20 | Exclusive License Agreement, dated December 9, 2022 by and between Novartis Pharma AG and the Registrant |
|---|
| 2022-05-12 | 10-Q | 10.2 | Lease Agreement, dated September 29, 2020 by and between ARE-SD Region No. 23, LLC and the Registrant, as amended |
|---|
| 2022-05-12 | 10-Q | 10.1 | Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended |
|---|
| 2022-03-24 | 10-K | 10.16 | Exclusive License Agreement, dated March 12, 2020, by and between Katmai Pharmaceuticals, Inc. and the Registrant |
|---|
| 2022-03-24 | 10-K | 10.13 | Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|